BioMarin Pharmaceutical Statistics
Total Valuation
BMRN has a market cap or net worth of $15.61 billion. The enterprise value is $15.65 billion.
| Market Cap | 15.61B |
| Enterprise Value | 15.65B |
Important Dates
The next estimated earnings date is Monday, July 29, 2024, after market close.
| Earnings Date | Jul 29, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
BMRN has 189.88 million shares outstanding. The number of shares has increased by 2.52% in one year.
| Shares Outstanding | 189.88M |
| Shares Change (YoY) | +2.52% |
| Shares Change (QoQ) | +9.94% |
| Owned by Insiders (%) | 0.87% |
| Owned by Institutions (%) | 100.94% |
| Float | 188.38M |
Valuation Ratios
The trailing PE ratio is 77.57 and the forward PE ratio is 44.73. BMRN's PEG ratio is 0.76.
| PE Ratio | 77.57 |
| Forward PE | 44.73 |
| PS Ratio | 6.32 |
| Forward PS | 5.42 |
| PB Ratio | 3.08 |
| P/FCF Ratio | 81.39 |
| PEG Ratio | 0.76 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 43.50, with an EV/FCF ratio of 81.60.
| EV / Earnings | 76.19 |
| EV / Sales | 6.33 |
| EV / EBITDA | 43.50 |
| EV / EBIT | 61.50 |
| EV / FCF | 81.60 |
Financial Position
The company has a current ratio of 2.74, with a Debt / Equity ratio of 0.21.
| Current Ratio | 2.74 |
| Quick Ratio | 1.55 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | 3.02 |
| Debt / FCF | 5.67 |
| Interest Coverage | 14.82 |
Financial Efficiency
Return on equity (ROE) is 4.20% and return on invested capital (ROIC) is 2.63%.
| Return on Equity (ROE) | 4.20% |
| Return on Assets (ROA) | 3.00% |
| Return on Capital (ROIC) | 2.63% |
| Revenue Per Employee | $726,740 |
| Profits Per Employee | $60,410 |
| Employee Count | 3,401 |
| Asset Turnover | 0.37 |
| Inventory Turnover | 0.50 |
Taxes
In the past 12 months, BMRN has paid $31.90 million in taxes.
| Income Tax | 31.90M |
| Effective Tax Rate | 13.44% |
Stock Price Statistics
The stock price has decreased by -4.27% in the last 52 weeks. The beta is 0.31, so BMRN's price volatility has been lower than the market average.
| Beta (5Y) | 0.31 |
| 52-Week Price Change | -4.27% |
| 50-Day Moving Average | 81.46 |
| 200-Day Moving Average | 87.07 |
| Relative Strength Index (RSI) | 49.08 |
| Average Volume (20 Days) | 4,089,627 |
Short Selling Information
The latest short interest is 3.56 million, so 1.88% of the outstanding shares have been sold short.
| Short Interest | 3.56M |
| Short Previous Month | 3.04M |
| Short % of Shares Out | 1.88% |
| Short % of Float | 1.89% |
| Short Ratio (days to cover) | 1.27 |
Income Statement
In the last 12 months, BMRN had revenue of $2.47 billion and earned $205.46 million in profits. Earnings per share was $1.06.
| Revenue | 2.47B |
| Gross Profit | 1.96B |
| Operating Income | 187.21M |
| Pretax Income | 237.35M |
| Net Income | 205.46M |
| EBITDA | 359.85M |
| EBIT | 254.53M |
| Earnings Per Share (EPS) | $1.06 |
Balance Sheet
The company has $1.05 billion in cash and $1.09 billion in debt, giving a net cash position of -$41.38 million or -$0.22 per share.
| Cash & Cash Equivalents | 1.05B |
| Total Debt | 1.09B |
| Net Cash | -41.38M |
| Net Cash Per Share | -$0.22 |
| Equity (Book Value) | 5.07B |
| Book Value Per Share | 26.72 |
| Working Capital | 1.90B |
Cash Flow
In the last 12 months, operating cash flow was $280.16 million and capital expenditures -$88.34 million, giving a free cash flow of $191.82 million.
| Operating Cash Flow | 280.16M |
| Capital Expenditures | -88.34M |
| Free Cash Flow | 191.82M |
| FCF Per Share | $1.02 |
Margins
Gross margin is 79.22%, with operating and profit margins of 7.57% and 8.31%.
| Gross Margin | 79.22% |
| Operating Margin | 7.57% |
| Pretax Margin | 9.60% |
| Profit Margin | 8.31% |
| EBITDA Margin | 14.56% |
| EBIT Margin | 10.30% |
| FCF Margin | 7.76% |
Dividends & Yields
BMRN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.52% |
| Shareholder Yield | -2.52% |
| Earnings Yield | 1.32% |
| FCF Yield | 1.23% |
Analyst Forecast
The average price target for BMRN is $105.45, which is 28.25% higher than the current price. The consensus rating is "Buy".
| Price Target | $105.45 |
| Price Target Difference | 28.25% |
| Analyst Consensus | Buy |
| Analyst Count | 21 |
| Revenue Growth Forecast (5Y) | 12.21% |
| EPS Growth Forecast (5Y) | 51.73% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BMRN has an Altman Z-Score of 5.91 and a Piotroski F-Score of 7.
| Altman Z-Score | 5.91 |
| Piotroski F-Score | 7 |